{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fontana RJ"],"funding":["NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","NCRR NIH HHS","National Cancer Institute","NCI NIH HHS"],"pagination":["1496-1505"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11296936"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["119(8)"],"pubmed_abstract":["<h4>Introduction</h4>The aim of this study is to describe the presenting features, genetic factors, and outcomes of 23 adults who developed liver injury after coronavirus disease 2019 (COVID-19) mRNA vaccination.<h4>Methods</h4>Patients with suspected COVID-19 vaccine hepatitis were enrolled into the Drug-Induced Liver Injury Network. Causality was assessed using the Drug-Induced Liver Injury Network expert opinion score. High-resolution HLA sequencing was undertaken using Illumina platform.<h4>Results</h4>Amongst the 16 high causality cases, median time to onset was 16 days, median age was 63 years, and 75% were female. The injury was hepatocellular in 75% with a median alanine aminotransferase of 497 U/L, and 37% had jaundice. An antinuclear antibody and smooth muscle antibody were detec"],"journal":["The American journal of gastroenterology"],"pubmed_title":["ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study."],"pmcid":["PMC11296936"],"funding_grant_id":["U01DK083027","U01DK100928","U01 DK065201","U01 DK065211","U01DK083020","U01 DK083020","U01 DK083027","U01 DK100928","U01DK065201","U01DK065211","U24 DK065176","U01DK065184","U24DK065176","U01 DK065184","Intramural Program","M01 RR000042"],"pubmed_authors":["Watkins PB","Shroff H","Fontana RJ","Vuppalanchi R","Gu J","Li YJ","Kleiner DE","Van Wagner LB","US DILIN study group"],"additional_accession":[]},"is_claimable":false,"name":"ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study.","description":"<h4>Introduction</h4>The aim of this study is to describe the presenting features, genetic factors, and outcomes of 23 adults who developed liver injury after coronavirus disease 2019 (COVID-19) mRNA vaccination.<h4>Methods</h4>Patients with suspected COVID-19 vaccine hepatitis were enrolled into the Drug-Induced Liver Injury Network. Causality was assessed using the Drug-Induced Liver Injury Network expert opinion score. High-resolution HLA sequencing was undertaken using Illumina platform.<h4>Results</h4>Amongst the 16 high causality cases, median time to onset was 16 days, median age was 63 years, and 75% were female. The injury was hepatocellular in 75% with a median alanine aminotransferase of 497 U/L, and 37% had jaundice. An antinuclear antibody and smooth muscle antibody were detec","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-03-18T13:25:34.331Z","creation":"2025-08-18T09:53:47.505Z"},"accession":"S-EPMC11296936","cross_references":{"pubmed":["38314748"],"doi":["10.14309/ajg.0000000000002702"]}}